Use of composition comprising histidine and proline for improving exercise performance, improving muscle function, or preventing, alleviating, or treating muscle diseases

A histidine and proline composition addresses the lack of combined supplementation efficacy by enhancing muscle strength, coordination, and mitochondrial function, effectively improving exercise performance and treating muscle diseases.

WO2026235526A1PCT designated stage Publication Date: 2026-11-12NOVMETAPHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/096750
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing amino acid supplementation strategies have not effectively investigated whether combined free histidine and proline supplementation can improve skeletal muscle performance, oxidative remodeling, and mitochondrial function under physiological conditions, and their effects on muscle wasting models are unclear.

Method used

A composition comprising histidine and proline as active ingredients, which can be administered in pharmaceutical, health functional food, or feed additive form, to enhance muscle strength, motor coordination, tolerance to fatigue, and mitochondrial function, inhibiting muscle atrophy and improving exercise performance and muscle function.

Benefits of technology

The composition significantly enhances muscle strength, motor coordination, tolerance to fatigue, and mitochondrial function, promoting oxidative muscle phenotypes and inhibiting muscle atrophy, thereby improving exercise performance and treating muscle diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026096750_12112026_PF_FP_ABST
    Figure KR2026096750_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a use of a composition comprising histidine and proline for improving exercise performance, improving muscle function, or preventing, alleviating or treating muscle diseases. More specifically, the present invention provides: a pharmaceutical composition, a food composition and a feed additive comprising histidine or a salt thereof and proline or a salt thereof as active ingredients; and a method for improving exercise performance, a method for improving muscle function, or preventing, alleviating, or treating muscle diseases, and a method for enhancing muscle strength, the methods using same, wherein the pharmaceutical composition, the food composition and the feed additive exhibit the effects of inhibiting muscle loss, increasing grip strength, increasing motor coordination, improving endurance, increasing resistance to muscle fatigue, increasing balance, increasing muscle energy production and inhibiting muscle atrophy, and thus can be used for exercise performance improvement and muscle strength enhancement, and also exhibit the effects of increasing muscle fiber size, inhibiting muscle loss, inhibiting muscle atrophy and increasing muscle energy production, and thus can be used for muscle function improvement or muscle disease prevention, alleviation or treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Use of a composition containing histidine and proline for improving exercise performance, improving muscle function, or preventing, improving, or treating muscle diseases

[0001] This application claims priority based on Korean Patent Application No. 10-2025-0060720 filed on May 9, 2025, and all contents disclosed in the specification and drawings of said application are incorporated into this application.

[0002] The present invention relates to the use of a composition comprising histidine and proline for improving exercise performance, improving muscle function, or preventing, improving, or treating muscle diseases. More specifically, the invention provides a pharmaceutical composition, a food composition, a feed additive, and a method for improving exercise performance, a method for improving muscle function or preventing, improving, or treating muscle diseases, and a method for strengthening muscle power, comprising histidine or a salt thereof and proline or a salt thereof as active ingredients, which exhibit effects such as inhibiting muscle loss, increasing grip strength, increasing motor coordination, improving endurance, increasing tolerance to muscle fatigue, increasing sense of balance, increasing muscle energy production, and inhibiting muscle atrophy, thereby being usable for improving exercise performance and strengthening muscle power, as well as effects such as increasing muscle fiber size, inhibiting muscle loss, inhibiting muscle atrophy, and increasing muscle energy production, thereby being usable for improving muscle function or preventing, improving, or treating muscle diseases.

[0003] Skeletal muscle function is a key factor determining overall systemic health and quality of life. The decline in skeletal muscle function is closely associated with aging, various diseases, and catabolic muscle wasting. While muscle mass has traditionally been considered the primary determinant of muscle strength, recent studies emphasize that muscle quality, defined by intrinsic metabolism and contractile efficiency, better predicts functional capacity. In particular, mitochondrial function plays a crucial role in maintaining muscle quality by regulating oxidative metabolism and cellular energy production. Impairment of mitochondrial biosynthesis and oxidative phosphorylation is a major characteristic of muscle dysfunction in various physiological and pathological conditions, including sarcopenia and muscle atrophy.

[0004] The availability of essential amino acids is a major regulator of skeletal muscle metabolism, and they are emerging not only as components of protein synthesis but also as signaling molecules that regulate metabolic pathways. Amino acid supplementation, including branched-chain amino acids (BCAAs) and some bioactive dipeptides, has been shown to improve muscle function. However, most studies have focused on individual amino acids, and it has not yet been fully determined whether defined amino acid combinations can cooperatively reprogram cellular metabolism to improve muscle function.

[0005] Histidine and proline are metabolically distinct amino acids that may influence complementary aspects of cellular metabolism. Histidine contributes to the synthesis of histidine-containing dipeptides (e.g., carnosine) for buffering and redox homeostasis (Non-patent Literature 1), while proline supports mitochondrial redox through the proline-P5C (1-pyrroline-5-carboxylate) cycle (Non-patent Literature 2). However, there have been no systematic studies investigating whether combined free histidine and proline supplementation can simultaneously improve skeletal muscle performance, oxidative remodeling, and mitochondrial function under physiological conditions, and whether such effects extend to muscle wasting models.

[0006] [Prior Art Literature]

[0007] [Non-patent literature]

[0008] (Non-patent Document 1) Brosnan, ME and JT Brosnan, Histidine Metabolism and Function. J Nutr, 2020. 150(Suppl 1): p. 2570S-2575S.

[0009] (Non-patent Document 2) Zheng, Y., et al., The proline cycle as an eukaryotic redox valve. J Exp Bot, 2021. 72(20): p. 6856-6866.

[0010] The object of the present invention is to provide a composition for improving exercise performance comprising histidine and proline as active ingredients.

[0011] Another objective of the present invention is to provide a composition for improving muscle function or preventing, improving, or treating muscle diseases, comprising histidine and proline as active ingredients.

[0012] Another objective of the present invention is to provide a composition for strengthening muscle strength comprising histidine and proline as active ingredients.

[0013] Another objective of the present invention is to provide a method for improving exercise performance, a method for improving muscle function, a method for preventing, improving or treating muscle diseases, and a method for strengthening muscle strength using histidine and proline.

[0014] Another objective of the present invention is to provide a use for a composition comprising histidine and proline as active ingredients for the manufacture of pharmaceuticals or health functional foods for improving exercise performance, improving muscle function, preventing, improving or treating muscle diseases, and strengthening muscle strength.

[0015] To solve the above-mentioned problem, the present invention provides a pharmaceutical composition for improving exercise performance comprising histidine or a pharmaceutically acceptable salt thereof and proline or a pharmaceutically acceptable salt thereof as active ingredients.

[0016] In addition, the present invention provides a health functional food composition for improving exercise performance comprising histidine or a food-grade acceptable salt thereof and proline or a food-grade acceptable salt thereof as active ingredients.

[0017] In addition, the present invention provides a feed additive for improving exercise performance comprising histidine or a food-grade acceptable salt thereof and proline or a food-grade acceptable salt thereof as active ingredients.

[0018] In addition, the present invention provides a method for improving exercise performance, comprising administering an effective amount of a composition containing histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients to an individual in need thereof.

[0019] In addition, the present invention provides a use of a composition comprising histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients for the manufacture of a drug or health functional food for improving exercise performance.

[0020] In the present invention, the composition may exhibit one or more of the following effects: i) to viii):

[0021] i) Inhibition of muscle loss;

[0022] ii) Increase in grip strength;

[0023] iii) Increase in motor coordination;

[0024] iv) Improvement of endurance;

[0025] v) Increased tolerance to muscle fatigue;

[0026] vi) Increased sense of balance;

[0027] vii) Increase in muscle energy production; and

[0028] viii) Inhibition of muscle atrophy.

[0029] Additionally, the present invention provides a pharmaceutical composition for improving muscle function or preventing or treating muscle diseases, comprising histidine or a pharmaceutically acceptable salt thereof and proline or a pharmaceutically acceptable salt thereof as active ingredients.

[0030] In addition, the present invention provides a health functional food composition for improving muscle function or preventing or improving muscle diseases, comprising histidine or a food-grade acceptable salt thereof and proline or a food-grade acceptable salt thereof as active ingredients.

[0031] In addition, the present invention provides a feed additive for improving muscle function or preventing or improving muscle diseases, comprising histidine or a food-grade acceptable salt thereof and proline or a food-grade acceptable salt thereof as active ingredients.

[0032] In addition, the present invention provides a method for improving muscle function or preventing, improving, or treating muscle diseases, comprising administering an effective amount of a composition containing histidine or a pharmaceutically or foodily acceptable salt thereof and proline or a pharmaceutically or foodily acceptable salt thereof as active ingredients to an individual in need thereof.

[0033] In addition, the present invention provides the use of a composition comprising histidine or a pharmaceutically or food-grade salt thereof and proline or a pharmaceutically or food-grade salt thereof as active ingredients for the manufacture of a pharmaceutical or health functional food for improving muscle function or preventing, improving, or treating muscle diseases.

[0034] In the present invention, the muscle disease may be a muscle disease caused by decreased muscle function, muscle atrophy, muscle wasting, or muscle degeneration.

[0035] In the present invention, the muscle disease may be one or more selected from the group consisting of atony, muscular atrophy, muscular dystrophy, myasthenia, cachexia, sarcopenia, cardiomyopathy, and cardiac atrophy.

[0036] In the present invention, the composition may exhibit one or more of the following effects: i) to viii):

[0037] i) Inhibition of muscle loss;

[0038] ii) Increase in grip strength;

[0039] iii) Increase in motor coordination;

[0040] iv) Improvement of endurance;

[0041] v) Increased tolerance to muscle fatigue;

[0042] vi) Increased sense of balance;

[0043] vii) Increase in muscle energy production; and

[0044] viii) Inhibition of muscle atrophy.

[0045] Furthermore, the present invention provides a composition for strengthening muscle strength comprising histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients.

[0046] In addition, the present invention provides a method for strengthening muscle strength, comprising administering an effective amount of a composition comprising histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients to an individual in need thereof.

[0047] In addition, the present invention provides a use of a composition comprising histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients for the manufacture of a muscle-strengthening agent or a health functional food.

[0048] The composition of the present invention comprising histidine or a salt thereof and proline or a salt thereof exhibits effects of increasing muscle strength, increasing motor coordination, increasing tolerance to muscle fatigue, increasing balance, and increasing muscle energy production, and can be utilized as a pharmaceutical, health functional food, or feed additive for improving exercise performance or strengthening muscles. Additionally, it exhibits effects of increasing muscle fiber size, inhibiting muscle atrophy and muscle loss, and increasing muscle energy production, and can be utilized as a pharmaceutical, health functional food, or feed additive for improving muscle function or preventing, improving, or treating various muscle diseases.

[0049] Figure 1 is a graph showing the effect of increasing grip strength following the administration of histidine and proline (HISPRO).

[0050] Figure 2 is a graph showing the change in expression of the muscle fiber gene Myh-1 in the gastrocnemius muscle following the administration of histidine and proline (HISPRO).

[0051] Figure 3 is a graph showing the changes in the expression of mitochondrial metabolic activity genes AK-4(a) and AGK(b) in the gastrocnemius muscle following the administration of histidine and proline (HISPRO).

[0052] Figure 4 is a graph showing the changes in the expression of mitochondrial metabolic activity genes Mfn-1(a) and Tfb2m(b) in soleus muscle following the administration of histidine and proline (HISPRO).

[0053] Figures 5a to 5h show the results of confirming the effects of histidine and proline (HISPRO) on improving muscle function and promoting oxidative muscle phenotypes. Specifically, Figure 5a shows an overview of the experiment, Figure 5b shows the results of grip strength measurements, Figure 5c shows the results of endurance measurements in the rotarod test, and Figure 5d shows the results of total distance measurements on the treadmill. Sidak multiple comparison tests were performed after one-way analysis of variance (ANOVA). Figure 5e shows representative H&E stained histological muscle fiber images of the gastrocnemius muscle [scale bar, 50 μm (H&E) and 100 μm (SDH)], Figure 5f shows the mean value of muscle fiber cross-sectional area (CSA), Figure 5g shows the distribution of muscle fiber CSA, Figure 5h shows the change in the proportion (% area) of SDH-positive (SDH) muscle fibers in the gastrocnemius muscle, Figure 5i shows in vivo oxygen consumption rate (VO2) (Unpaired Student's t-tests. *p < 0.05, **p < 0.01, ****p < 0.0001.), and Figure 5j shows in vivo oxygen consumption rate (VO2) over time. Data are presented as mean ± standard error (SEM). Unpaired Student's t-test. *p < 0.05.

[0054] Figures 6a to 6g show the effects of histidine and proline (HISPRO) on promoting skeletal muscle mitochondrial biosynthesis and oxidative metabolism. Specifically, Figure 6a shows the results of gene expression involved in mitochondrial biosynthesis and maintenance in the gastrocnemius muscle (normalized to Gapdh), Figure 6b shows the results of gene expression related to fatty acid oxidation and oxidative metabolism in the gastrocnemius muscle (normalized to Gapdh), Figure 6c shows the mtDNA copy number of the gastrocnemius muscle measured by D-loop quantification, Figure 6d shows the citric acid synthase activity of the gastrocnemius muscle, Figure 6e shows a representative Western blot image of OXPHOS complex protein expression in the gastrocnemius muscle, Figure 6f shows the quantification levels of each complex protein, and Figure 6g shows gene expression specific to muscle fiber type in the gastrocnemius muscle (normalized to β-actin or Hprt) (Unpaired Student's t-tests. *p < 0.05, **p < 0.01.).

[0055] Figure 7 shows the gene expression involved in mitochondrial biosynthesis and metabolism in skeletal muscle tissues according to experimental groups. Specifically, Figure 7A and B show gene expression in the gastrocnemius muscle, C and D in the soleus muscle, and E and F in the extensor digitorum longus muscle. Data were presented as box plots (median, interquartile range, min-max whiskers). Sidak multiple comparison tests were performed after one-way analysis of variance (ANOVA) (*p < 0.05, **p < 0.01).

[0056] Figures 8a to 8h show the activating effects of histidine and proline (HISPRO) on SIRT1-dependent deacetylation and energy metabolism signaling. Specifically, Figures 8a and 8b show NAD in the gastrocnemius muscle. + Gene expression involved in synthesis, Fig. 8c is NAD of the gastrocnemius muscle + / NADH ratio, Fig. 8d shows representative Western blot images and quantified protein levels of PGC-1α in gastrocnemius muscle, Fig. 8e shows representative IP-Western blot images and quantifications of FOXO1 and LKB1 acetylation in gastrocnemius muscle, Fig. 8f shows representative Western blot images and quantified protein levels of p-AMPK and total AMPK in gastrocnemius muscle, Fig. 8g shows gene expression involved in mitochondrial biosynthesis and function in C2C12 myotube cells in the presence of the SIRT1 inhibitor EX-527 (n=5 per group), and Fig. 8h shows representative images of mitochondria stained with MitoTracker and mitochondrial density quantification results in C2C12 myotube cells (n=5 per group) (scale bar, 25 μm. Unpaired Student's t-tests, *p < 0.05, **p < 0.01, ***p < 0.001.).

[0057] Figure 9 shows the expression of OXPHOS complex proteins in C2C12 muscle cells in the presence of the SIRT1 inhibitor EX-527. Data are presented as mean ± standard error (independent samples t-test. *p < 0.05, **p < 0.01).

[0058] Figures 10a to 10g show the effects of histidine and proline (HISPRO) on inhibiting dexamethasone-induced muscle atrophy and improving mitochondrial function. Specifically, Figure 10a shows an overview of the experiment, Figure 10b shows grip strength, Figure 10c shows the results of endurance evaluation in the rotarod test, Figure 10d shows gene expression involved in mitochondrial biosynthesis and maintenance in the gastrocnemius muscle, Figure 10e shows citric acid synthase activity in the gastrocnemius muscle, Figure 10f shows atrophy-related gene expression in the gastrocnemius muscle (normalized by Hprt), and Figure 10g shows Atrogin-1 protein expression in the gastrocnemius muscle (Unpaired Student's t-tests, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).

[0059] The present invention will be described in more detail below.

[0060] As mentioned above, due to the rapid increase in the elderly population, the development of treatments for sarcopenia associated with skeletal muscle atrophy is actively underway; however, to date, there are no drugs that demonstrate a distinct therapeutic effect.

[0061] Accordingly, the inventors have confirmed that the combination of histidine and proline not only significantly enhances muscle strength, motor coordination, tolerance to muscle fatigue, sense of balance, and muscle energy production, but also suppresses the expression of various genes related to aging and muscle atrophy, and promotes the expression of anti-aging and antioxidant-related genes, including mitochondrial function, thereby exhibiting excellent effects in improving exercise performance, strengthening muscle power, improving muscle function, and preventing, improving, or treating muscle diseases, and have completed the present invention.

[0062] Accordingly, the first aspect of the present invention relates to a composition for improving exercise performance comprising histidine or a salt thereof and proline or a salt thereof, consisting essentially of said histidine or a salt thereof and proline or a salt thereof, or consisting of said histidine or a salt thereof and proline or a salt thereof.

[0063] Specifically, the composition comprises histidine or a pharmaceutically acceptable salt thereof and proline or a pharmaceutically acceptable salt thereof, is essentially composed of said histidine or a pharmaceutically acceptable salt thereof and proline or a pharmaceutically acceptable salt thereof, or is composed of said histidine or a pharmaceutically acceptable salt thereof and proline or a pharmaceutically acceptable salt thereof; a health functional food composition for improving exercise performance comprises histidine or a foodily acceptable salt thereof and proline or a foodily acceptable salt thereof, is essentially composed of said histidine or a foodily acceptable salt thereof and proline or a foodily acceptable salt thereof, or is composed of said histidine or a foodily acceptable salt thereof and proline or a foodily acceptable salt thereof; Alternatively, it may be a feed additive for improving exercise performance comprising histidine or its salt and proline or its salt, consisting essentially of said histidine or its salt and proline or its salt, or consisting of said histidine or its salt and proline or its salt.

[0064] In relation to the first aspect above, the present invention provides a method for improving exercise performance, comprising administering an effective amount of a composition comprising histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients to an individual in need thereof.

[0065] In relation to the first aspect above, the present invention also provides for use in a composition comprising histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients for use in improving exercise performance.

[0066] In relation to the first aspect above, the present invention also provides for the use of a composition comprising histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients for the manufacture of a pharmaceutical or health functional food for improving exercise performance.

[0067] In the present invention, the term "exercise performance ability" refers to the ability to perform physical movements in daily life or sports quickly, strongly, for a long time, and skillfully. Exercise performance ability is defined by factors such as muscle strength, sense of balance, motor coordination, agility, and endurance. In addition, in the present invention, improving exercise performance ability is considered a beneficial physiological effect even for people performing daily physical activities that are not related to exercise.

[0068] In this invention, the term "muscle fatigue" refers to a state in which the ability to perform physical activities is temporarily reduced due to high-intensity exercise or prolonged exercise, and is accompanied by a decrease in muscle contractility. Muscle fatigue may manifest as a feeling of fatigue, reduced endurance, reduced explosiveness, or symptoms of lethargy.

[0069] In the present invention, the term "endurance" is defined as resistance to fatigue. This refers to resistance to fatigue that occurs during exercise sustained at submaximal (less than maximum intensity) levels or during intense exercise. Typically, endurance exercise lasts for 30 minutes or longer. In particular, exercise lasting 4 to 5 hours or longer is also referred to as ultra-endurance exercise. Furthermore, in the present invention, the enhancement of endurance is considered a beneficial physiological function for performing exercises without time limits (recreational running, walking, swimming, cycling, gymnastics training, etc.).

[0070] According to the present invention, histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof may be included in a weight ratio of 1 to 10:1. For example, a preferred weight ratio of histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof may be 1 to 9.5:1, 1 to 9:1, 1 to 8.5:1, 1 to 8:1, 1 to 7.5:1, 1 to 7:1, 1 to 6.5:1, 1 to 6:1, 1 to 5.5:1, 1 to 5:1, 1 to 4.5:1, 1 to 4:1, 1 to 3.5:1, 1 to 3:1, 1 to 2.5:1, 1 to 2:1, 1 to 1.5:1, or 1:1, but is not limited thereto.

[0071] In a specific embodiment of the present invention, the effect of histidine and proline on improving motor performance was evaluated by performing grip strength measurements, limb hanging tests, and sensorimotor function evaluations on an animal model treated with a combination of histidine and proline.

[0072] As a result, as shown in Figure 1, the group administered histidine and proline (HISPRO) showed a significant increase in maximum muscle strength and hanging time compared to the control group treated with the vehicle, and sensorimotor function was significantly improved, confirming that it exhibited effects of enhancing muscle strength, motor coordination, tolerance to muscle fatigue, and sense of balance. However, in the group administered zinc along with L-histidine and L-proline, grip strength decreased, indicating that zinc actually reduced the efficacy of L-histidine and L-proline. Therefore, the composition containing histidine and proline according to the present invention can be utilized in various ways, such as pharmaceuticals, health functional foods, and feed additives for the purpose of improving exercise performance, and zinc may not be included.

[0073] In another specific embodiment of the present invention, the effects of histidine and proline on improving muscle function and promoting oxidative muscle phenotype were evaluated by performing grip strength tests, rotarod tests, and treadmill tests on animal models treated with histidine and proline (HISPRO).

[0074] As a result, as shown in Figures 5a to 5j, the HISPRO administration group showed a significant increase in grip strength compared to the control group, and the endurance in the rotarod test and total distance traveled on the treadmill were significantly improved. While the histidine-only group showed a slight improvement in grip strength, the proline-only group showed only minimal effect, confirming that combined administration of histidine and proline is necessary for complete improvement in motor coordination and endurance. In addition, histological analysis revealed that the muscle fiber cross-sectional area (CSA) in the HISPRO administration group significantly increased and the proportion of SDH (succinate dehydrogenase) positive muscle fibers was higher, confirming a transition to an oxidative muscle phenotype, and the oxygen consumption rate (VO2) also significantly increased.

[0075] In another specific embodiment of the present invention, the effects of histidine and proline on improving mitochondrial function and oxidative metabolism were evaluated by analyzing mitochondrial-related gene expression, mtDNA copy number, citric acid synthase activity, and OXPHOS complex protein levels in skeletal muscle of an animal model treated with HISPRO.

[0076] As a result, as shown in Figures 6a to 6g, the expression of genes related to mitochondrial biosynthesis (Pgc-1α, ERRα, Tfam, Tfb1m, Gabpb1), genes related to mitochondrial kinetics (Mfn2, Drp1), genes related to metabolic regulation (FoxO1, Sirt1), and genes related to fatty acid oxidation (PPARα, mCAD, Acox1, FH) in the HISPRO administration group was significantly increased compared to the control group. In addition, the mtDNA copy number and citric acid synthase activity were significantly increased, and the levels of OXPHOS complex proteins (complexes I, III, IV, V) were significantly increased. In addition, it was confirmed that genes related to Type I (slow-twitch) muscle fibers (Tnnc1, Tnnt1, Sln, Mef2c, Myh7) are upregulated and genes related to Type II (fast-twitch) muscle fibers (Tnnc2, Six1, Sox6, Myh1) are downregulated, thereby confirming that HISPRO promotes mitochondrial biosynthesis and induces a transition to an oxidative muscle phenotype. Therefore, it was confirmed that the composition containing histidine and proline according to the present invention has the effect of increasing muscle energy production through the improvement of mitochondrial function and the promotion of oxidative metabolism.

[0077] In another specific embodiment of the present invention, NAD in the skeletal muscle of an animal model treated with HISPRO + Synthesis-related gene expression, NAD + The activating effects of histidine and proline on the SIRT1-PGC-1α-AMPK signaling axis were evaluated by analyzing the / NADH ratio, protein levels, and acetylation levels.

[0078] As a result, as shown in Figures 8a to 8f, NAD in the HISPRO administration group + The expression of synthesis-related genes NAMPT and NMNAT significantly increased compared to the control group, and NAD + It was confirmed that SIRT1 activity was enhanced by a significant increase in the / NADH ratio. In addition, PGC-1α protein levels increased in the HISPRO administration group, and immunoprecipitation analysis confirmed that deacetylation by SIRT1 increased, as the acetylation of FOXO1 and LKB1 significantly decreased. Furthermore, phosphorylation of AMPK significantly increased, confirming that HISPRO activates the SIRT1-PGC-1α-AMPK signaling axis. Therefore, it was confirmed that the composition containing histidine and proline according to the present invention has the effect of improving energy metabolism in skeletal muscle through the activation of the SIRT1-PGC-1α-AMPK signaling axis.

[0079] In another specific embodiment of the present invention, the SIRT1-dependent and SIRT1-independent mechanisms of HISPRO were confirmed by evaluating the effects of HISPRO on mitochondrial biosynthesis and OXPHOS expression in C2C12 myotube cells treated with EX-527, a SIRT1 inhibitor.

[0080] As a result, as shown in Figures 8g and 8h, the expression of mitochondrial biosynthesis-related genes (Tfam, Tfb1m, Tfb2m) and mitochondrial density were significantly increased in the HISPRO-treated group, but this increase was significantly suppressed in the EX-527 co-treated group, confirming that the mitochondrial biosynthesis effect of HISPRO is highly dependent on SIRT1 activity. Meanwhile, even under conditions of SIRT1 inhibition, the OXPHOS complex protein levels in the HISPRO-treated group maintained a higher tendency compared to the control group (Figure 9), which suggests that the effect of HISPRO on OXPHOS may include additional SIRT1-independent mechanisms, such as a direct contribution to the mitochondrial electron transport chain through the proline-P5C cycle, in addition to SIRT1-dependent mechanisms.

[0081] In addition, histidine or a salt thereof and proline or a salt thereof according to the present invention may be administered to an individual for the purpose of improving exercise performance. Accordingly, a method for improving exercise performance is provided, comprising the step of administering histidine or a salt thereof and proline or a salt thereof to an individual who requires it.

[0082] A second aspect of the present invention relates to a composition for improving muscle function or preventing, improving, or treating muscle diseases, comprising histidine or a salt thereof and proline or a salt thereof, consisting essentially of said histidine or a salt thereof and proline or a salt thereof, or consisting of said histidine or a salt thereof and proline or a salt thereof.

[0083] Specifically, the composition is a pharmaceutical composition for improving muscle function or preventing or treating muscle diseases, comprising histidine or a pharmaceutically acceptable salt thereof and proline or a pharmaceutically acceptable salt thereof, consisting essentially of said histidine or a pharmaceutically acceptable salt thereof and proline or a pharmaceutically acceptable salt thereof, or consisting of said histidine or a pharmaceutically acceptable salt thereof and proline or a pharmaceutically acceptable salt thereof; A health functional food composition for improving muscle function or preventing or improving muscle disease, comprising histidine or a food-grade acceptable salt thereof and proline or a food-grade acceptable salt thereof, essentially composed of said histidine or a food-grade acceptable salt thereof and proline or a food-grade acceptable salt thereof, or composed of said histidine or a food-grade acceptable salt thereof and proline or a food-grade acceptable salt thereof; or a feed additive for improving muscle function or preventing or improving muscle disease, comprising said histidine or a salt thereof and proline or a salt thereof, essentially composed of said histidine or a salt thereof and proline or a salt thereof, or composed of said histidine or a salt thereof and proline or a salt thereof.

[0084] In relation to the second aspect above, the present invention provides a method for improving muscle function or preventing, improving, or treating muscle diseases, comprising administering an effective amount of a composition comprising histidine or a pharmaceutically or food-acceptable salt thereof and proline or a pharmaceutically or food-acceptable salt thereof as active ingredients to an individual in need thereof.

[0085] In relation to the second aspect above, the present invention also provides for the use of a composition comprising histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients for use in improving muscle function or preventing, improving, or treating muscle diseases.

[0086] In relation to the second aspect above, the present invention also provides for the use of a composition comprising histidine or a pharmaceutically or food-grade salt thereof and proline or a pharmaceutically or food-grade salt thereof as active ingredients for the manufacture of a pharmaceutical or health functional food for improving muscle function or preventing, improving, or treating muscle diseases.

[0087] In the present invention, the muscle disease is preferably a muscle disease reported in the art that results from decreased muscle function, muscle atrophy, muscle wasting, or muscle degeneration, and may be one or more selected from the group consisting of atony, muscular atrophy, muscular dystrophy, myasthenia gravis, cachexia, sarcopenia, cardiomyopathy, and cardiac atrophy, but is not limited thereto.

[0088] The above-mentioned decline in muscle function, muscle atrophy, muscle wasting, or muscle degeneration may be caused by genetic factors, acquired factors, diseases that cause muscle loss or weakening, or aging, and according to one embodiment, may be caused by aging. Alternatively, the decline in muscle function, muscle atrophy, muscle wasting, or muscle degeneration may be a side effect of disease treatment, for example, a side effect of anticancer treatment. The above-mentioned muscle wasting is characterized by a gradual loss of muscle mass, and the weakening and degeneration of muscles, particularly skeletal muscles, voluntary muscles, and cardiac muscles. In particular, in the present invention, "muscle disease" may be a disease in which decline in muscle function, muscle atrophy, muscle wasting, or muscle degeneration occurs due to the aging of the muscle itself, for example, skeletal muscles or cardiac muscles, regardless of motor neuron death in the central nervous system, or a disease in which decline in muscle function, muscle atrophy, muscle wasting, or muscle degeneration occurs due to genetic mutations.

[0089] As used in this specification, "old age" or "aging" is generally defined as a noticeable decrease or loss of muscle mass starting around the age of 50, and sarcopenia (age-related muscle loss) may become more pronounced around the age of 60.

[0090] The above-mentioned decline in muscle function, muscle atrophy, muscle wasting, or muscle degeneration may be caused by various factors, and specifically, may be caused by the following factors, but is not limited thereto:

[0091] i) Catabolic stress: Muscle dysfunction, muscle atrophy, muscle wasting, or muscle degeneration caused by the acceleration of muscle protein breakdown and increased expression of muscle breakdown-related genes such as Atrogin-1 and MuRF1 due to the administration of glucocorticoids (e.g., steroid drugs such as dexamethasone), sepsis, trauma, or surgery;

[0092] ii) Aging: Decline in muscle function, muscle atrophy, muscle wasting, or muscle degeneration (sarcopenia) resulting from a decrease in muscle protein synthesis ability and reduced mitochondrial function with age;

[0093] iii) Nutritional deficiency: Decline in muscle function, muscle atrophy, muscle wasting, or muscle degeneration resulting from muscle protein being used as an energy source due to insufficient protein or energy intake;

[0094] iv) Inflammatory diseases: muscle decline, muscle atrophy, muscle wasting, or muscle degeneration caused by accelerated muscle breakdown by inflammatory cytokines in a state of cachexia due to cancer, chronic inflammation, etc.; or

[0095] v) Immobilization or lack of exercise: Muscle dysfunction, muscle atrophy, muscle wasting, or muscle degeneration resulting from non-use of muscles due to prolonged bed rest, limb immobilization, or a zero-gravity environment.

[0096] Myosin heavy chain 1 (Myh-1), adenylate kinase 4 (AK-4), acylglycerol kinase (AGK), mitofusin-1 (Mfn-1), and transcription factor B2 mitochondrial (Tfb2m) are known to be genes involved in muscle function. Accordingly, in a specific embodiment of the present invention, the expression levels of the above genes in the muscles of an animal model treated with L-histidine and L-proline were confirmed, thereby evaluating the effects of histidine and proline on improving muscle function and preventing, improving, or treating muscle diseases.

[0097] As a result, as confirmed in Figures 2 to 4, it was confirmed that the expression levels of the five types of genes in the gastrocnemius and soleus muscles increased in the histidine and proline administration groups compared to the control group. Therefore, the composition according to the present invention, comprising histidine or its salt and proline or its salt, helps in muscle energy production by increasing the expression of mitochondrial-mediated energy metabolism regulators and inhibits muscle atrophy, thereby effectively being used not only to improve muscle function but also to treat muscle diseases caused by muscle decline, muscle atrophy, muscle wasting, or muscle degeneration.

[0098] In another specific embodiment of the present invention, the effects of HISPRO administration on muscle protection and mitochondrial function recovery were evaluated in a dexamethasone-induced muscle atrophy mouse model.

[0099] As a result, as shown in Figures 10a to 10g, grip strength and rotarod performance, which were significantly reduced by dexamethasone treatment, were significantly restored by HISPRO administration. In addition, the expression of genes related to mitochondrial biosynthesis and function (Pgc-1α, Nrf1, Tfam, Tfb1m, Gabpb1, FH) that were inhibited by dexamethasone was significantly restored by HISPRO administration, and citric acid synthase activity also significantly increased, confirming that mitochondrial function was restored. Furthermore, the expression of Atrogin-1 and MuRF1, which are genes related to muscle atrophy, and the level of Atrogin-1 protein were significantly reduced by HISPRO administration, confirming that the protein degradation pathway was inhibited. Therefore, it was confirmed that the composition containing histidine and proline according to the present invention has an effect of inhibiting muscle loss and muscle atrophy through the restoration of mitochondrial function and the inhibition of gene expression related to muscle atrophy.

[0100] In the present invention, the disease resulting from the heart muscle abnormality may be, for example, cardiomyopathy or cardiac atrophy occurring primarily in the heart muscle itself, but is not limited thereto.

[0101] Cardiac atrophy is induced by starvation, wasting diseases (such as cancer), or aging; as a result, myocardial fibers become dry and thin, and nuclei become condensed, leading to disparity in size. Consequently, the volume of muscle fascicles decreases, the entire heart shrinks, subpericardial adipose tissue significantly diminishes, and the coronary arteries become curved. A wasting pigment called lipofuscine appears as a brown pigment at both ends of the myocardial fiber nuclei, and along with the reduction in adipose tissue, the entire heart takes on a brownish tint.

[0102] The most common type of muscular dystrophy is X-chromosome-linked Duchenne / Becker muscular dystrophy; however, there are various other types depending on the type of protein forming the muscle membrane, such as limb-girdle, facioscapulohumeral, myorigic, and Fukuyama types.

[0103] Duchenne muscular dystrophy (DMD) is one of the most destructive and progressive hereditary muscular dystrophies to manifest in childhood. It is caused by mutations in the dystrophin gene and is a recessive X-linked genetic disorder affecting 1 in 3,500 male births. Notably, symptoms can also appear in female carriers. Dystrophin is a key member of the dystrophin-associated protein complex (DAPC), which acts as the primary link between the cytoskeleton and the extracellular matrix (ECM) of muscle fibers. A deficiency in functional dystrophin leads to the degradation of DAPC, resulting in the loss of stable cytoskeleton-ECM connections, weakening the sarcolemma, and making muscle fibers susceptible to contractile damage.

[0104] The first clinical signs appear during childhood between the ages of 2 and 3, when children exhibit delayed motor development, such as difficulty walking or jumping. Dystrophy first affects the proximal muscles and then spreads to the muscles of the distal limbs, eventually leading pediatric patients to use wheelchairs by the age of 12. Dystrophy eventually reaches the respiratory muscles, reaching a stage where mechanical ventilation is required. The heart muscle also weakens, ultimately leading to cardiomyopathy. In fact, respiratory and heart failure are the two leading causes of death in DMD.

[0105] Despite all therapeutic advancements over the past few decades, no cure for DMD has yet been approved. Nevertheless, improvements in treatment protocols and symptom management can delay the progression of DMD and improve patients' quality of life. With appropriate treatment, the life expectancy of DMD patients today is approximately 28 years. The current standard treatment is corticosteroid therapy, which reduces chronic inflammation and delays muscle damage caused by inflammation. In particular, long-term use of corticosteroids leads to various side effects, including weight gain, growth retardation, and osteoporosis.

[0106] In addition, histidine or its salt and proline or its salt according to the present invention may be administered to an individual for the purpose of improving muscle function or preventing, improving, or treating muscle diseases. Accordingly, a method for improving muscle function or preventing, improving, or treating muscle diseases is provided, comprising the step of administering histidine or its salt and proline or its salt to an individual who requires it.

[0107] A third aspect of the present invention relates to a composition for strengthening muscle strength comprising histidine or a salt thereof and proline or a salt thereof, consisting essentially of said histidine or a salt thereof and proline or a salt thereof, or consisting of said histidine or a salt thereof and proline or a salt thereof.

[0108] Specifically, the composition comprises histidine or a pharmaceutically acceptable salt thereof and proline or a pharmaceutically acceptable salt thereof, is essentially composed of said histidine or a pharmaceutically acceptable salt thereof and proline or a pharmaceutically acceptable salt thereof, or is composed of said histidine or a pharmaceutically acceptable salt thereof and proline or a pharmaceutically acceptable salt thereof; a health functional food composition for muscle strengthening comprises histidine or a foodily acceptable salt thereof and proline or a foodily acceptable salt thereof, is essentially composed of said histidine or a foodily acceptable salt thereof and proline or a foodily acceptable salt thereof, or is composed of said histidine or a foodily acceptable salt thereof and proline or a foodily acceptable salt thereof; Alternatively, it may be a feed additive for muscle strengthening that comprises histidine or its salt and proline or its salt, is essentially composed of said histidine or its salt and proline or its salt, or is composed of said histidine or its salt and proline or its salt.

[0109] In relation to the third aspect above, the present invention provides a method for strengthening muscle strength, comprising administering an effective amount of a composition comprising histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients to an individual in need thereof.

[0110] In relation to the third aspect above, the present invention also provides for the use of a composition comprising histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients for use in strengthening muscles.

[0111] In relation to the third aspect above, the present invention also provides for the use of a composition comprising histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients for the manufacture of a muscle-strengthening agent or a health functional food.

[0112] The term "muscle strength enhancement" in this invention refers to the enhancement of physical performance, enhancement of maximum endurance, increase in muscle mass, enhancement of muscle recovery, reduction of muscle fatigue, improvement of energy balance, or a combination thereof.

[0113] As described in the first and second aspects above, histidine or its salt and proline or its salt according to the present invention not only exhibit effects of increasing muscle strength, increasing motor coordination, increasing tolerance to muscle fatigue, and increasing balance, but also effects of increasing muscle fiber size, inhibiting muscle atrophy, inhibiting muscle loss, and increasing muscle energy production; thus, they can be utilized in various ways, such as pharmaceuticals, health functional foods, and feed additives, for the purpose of strengthening muscle strength.

[0114] Additionally, histidine or its salt and proline or its salt according to the present invention may be administered to an individual for the purpose of strengthening muscle strength. Accordingly, a method for strengthening muscle strength is provided, comprising the step of administering histidine or its salt and proline or its salt to an individual who requires it.

[0115] As used in the present invention, the term "prevention" refers to any act of suppressing or delaying the onset of muscle disease by administering a composition according to the present invention.

[0116] The term "improvement" as used in the present invention refers to any action that at least reduces parameters related to the condition being treated, such as the degree of symptoms.

[0117] As used in the present invention, the term "treatment" refers to any act in which symptoms caused by a muscle disease are improved or beneficially altered by the administration of a composition according to the present invention.

[0118] The term "increase" used in the present invention, for example, an increase in the expression of a specific biomarker gene or protein, means that when compared under the same conditions to a control group that has not administered the active ingredient of the present invention or a composition containing, essentially composed of, or composed of the active ingredient, the expression is about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 35% or more, about 40% or more, about 45% or more, or about 50% or more.

[0119] The terms “decrease or reduction” or “suppression” used in the present invention, for example, the decrease or suppression of expression of a specific biomarker gene or protein, means that when compared under the same conditions to a control group that has not administered the active ingredient of the present invention or a composition containing, essentially composed of, or composed of the active ingredient, the expression is about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 35% or more, about 40% or more, about 45% or more, about 50% or more, about 55% or more, about 60% or more, about 65% or more, about 70% or more, or about 75% or more.

[0120] The terms “improvement or enhancement” used in the present invention, for example, improvement in exercise performance or improvement in muscle function, mean an increase of about 5% or more, about 10% or more, about 15% or more, or about 20% or more when compared under the same conditions to a control group that has not administered the active ingredient of the present invention or a composition containing, essentially composed of, or composed of the active ingredient.

[0121] In the present invention, the term "pharmaceutically acceptable" means physiologically acceptable and, when administered to humans, does not typically cause an allergic reaction or a similar reaction, and the salt is preferably an acid adduct formed by a pharmaceutically acceptable free acid.

[0122] The above pharmaceutically acceptable salt may be an acid addition salt formed using an organic acid or an inorganic acid, and the organic acid includes, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, malic acid, maleic acid, malonic acid, fumaric acid, succinic acid, succinic acid monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, dichloroacetic acid, aminooxyacetic acid, benzenesulfonic acid, p-toluenesulfonic acid, or methanesulfonic acid. The inorganic acid includes, for example, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid, or boric acid. The acid addition salt may preferably be in the form of a hydrochloride or acetate, and more preferably in the form of a hydrochloride.

[0123] In addition, other possible salt forms include GABA, gabapentin, pregabalin, nicotinate, adipate, hemimalonicate, cysteine, acetylcysteine, methionine, arginine, lysine, ornithine, or aspartate.

[0124] Additionally, the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers may further comprise, for example, a carrier for oral administration or a carrier for parenteral administration. Carriers for oral administration may comprise lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, etc. Carriers for parenteral administration may comprise water, suitable oil, saline solution, aqueous glucose and glycol, etc. Additionally, stabilizers and preservatives may further comprise. Suitable stabilizers include antioxidants such as sodium bisulfite, sodium sulfite, or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol. Other pharmaceutically acceptable carriers may be referenced from the following literature (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995).

[0125] The pharmaceutical composition of the present invention can be administered to mammals, including humans, by any method. For example, it can be administered orally or parenterally, and parenteral administration methods may include, but are not limited to, intravenous, intramuscular, intra-arterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual, or rectal administration.

[0126] The pharmaceutical composition of the present invention may be formulated into an oral or parenteral administration formulation according to the administration route described above. When formulating, it may be prepared using one or more buffers (e.g., saline solution or PBS), carbohydrates (e.g., glucose, mannose, sucrose, or dextran, etc.), antioxidants, bacteriostatic agents, chelating agents (e.g., EDTA or glutathione), fillers, extenders, binders, adjuvants (e.g., aluminum hydroxide), suspending agents, thickeners, wetting agents, disintegrants or surfactants, diluents or excipients.

[0127] Solid dosage forms for oral administration include tablets, pills, powders, granules, liquids, gels, syrups, slurries, suspensions, or capsules, and such solid dosage forms may be prepared by mixing at least one excipient, for example, starch (including corn starch, wheat starch, rice starch, potato starch, etc.), calcium carbonate, sucrose, lactose, dextrose, sorbitol, mannitol, xylitol, erythritol, maltitol, cellulose, methyl cellulose, sodium carboxymethylcellulose and hydroxypropylmethylcellulose, or gelatin, with the pharmaceutical composition of the present invention. For example, a tablet or a sugar-coated tablet may be obtained by combining an active ingredient with a solid excipient, grinding the mixture, adding a suitable auxiliary agent, and processing it into a granular mixture.

[0128] In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid formulations for oral administration include suspensions, oral liquids, emulsions, or syrups, and may contain various excipients, such as humectants, sweeteners, flavorings, or preservatives, in addition to commonly used simple diluents like water or liquid paraffin.

[0129] In addition, cross-linked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may be added as a disintegrant depending on the case, and may additionally include anticoagulants, lubricants, wetting agents, fragrances, emulsifiers, and preservatives.

[0130] When administered parenterally, the pharmaceutical composition of the present invention may be formulated in the form of an injectable, a transdermal agent, and a nasal inhalant with a suitable parenteral carrier according to methods known in the art. The injectable must be sterile and protected from contamination by microorganisms such as bacteria and fungi. Examples of suitable carriers for the injectable may include, but are not limited to, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), mixtures thereof, and / or a solvent or dispersion medium comprising vegetable oil. More preferably, suitable carriers may include Hanks' solution, Ringer's solution, PBS (phosphate buffered saline) containing triethanolamine or sterile water for injection, isotonic solutions such as 10% ethanol, 40% propylene glycol, and 5% dextrose. To protect the above-mentioned injectable from microbial contamination, various antimicrobial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc. may be additionally included. In addition, the above-mentioned injectable may, in most cases, additionally include isotonic agents such as sugars or sodium chloride.

[0131] Transdermal formulations include forms such as ointments, creams, lotions, gels, topical solutions, pastes, liniments, and aerosols. In the above, 'transdermal administration' means administering a pharmaceutical composition topically to the skin so that an effective amount of the active ingredient contained in the pharmaceutical composition is delivered into the skin.

[0132] In the case of inhalation formulations, the compound used according to the present invention can be conveniently delivered in the form of an aerosol spray from a pressurized pack or atomizer using a suitable propellant, e.g., dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. In the case of pressurized aerosols, the dosage unit can be determined by providing a valve that delivers a metered amount. For example, gelatin capsules and cartridges used in inhalers or blowers can be formulated to contain the compound and a powder mixture of a suitable powder base, such as lactose or starch. Formulations for parenteral administration are described in the literature, which is a prescription generally known in all pharmaceutical chemistry (Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour).

[0133] The pharmaceutical composition of the present invention may provide desirable effects of improving exercise performance, improving muscle function, and / or preventing, improving, or treating muscle diseases when containing an effective amount of histidine or a pharmaceutically or food-acceptable salt thereof and proline or a pharmaceutically or food-acceptable salt thereof. In this invention, the term "effective amount" refers to an amount that produces a response greater than that of a negative control, and preferably refers to an amount sufficient to improve exercise performance, improve muscle function, and / or prevent, improve, or treat muscle diseases. The pharmaceutical composition of the present invention may contain 0.01 to 99.9% of histidine or a pharmaceutically acceptable salt thereof and proline or a pharmaceutically acceptable salt thereof, and the remainder may be a pharmaceutically acceptable carrier. The effective amount of histidine or a pharmaceutically acceptable salt thereof and proline or a pharmaceutically acceptable salt thereof included in the pharmaceutical composition of the present invention will vary depending on the form in which the composition is manufactured into a product, etc.

[0134] The total effective amount of the pharmaceutical composition of the present invention may be administered to a patient as a single dose, or administered via a fractionated treatment protocol involving multiple doses administered over a long period. The pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the patient's condition. For example, when administered to a human, it may be administered in one or several doses, preferably in an amount of 20 to 2,000 mg, more preferably 22 to 1,500 mg, and even more preferably 25 to 1,000 mg per kg of body weight per day, based on histidine or its pharmaceutically acceptable salt and proline or its pharmaceutically acceptable salt. However, since the effective dosage for a patient is determined by considering various factors such as the patient's age, weight, health status, gender, severity of the disease, diet, and excretion rate, as well as the route of administration and number of treatments of the pharmaceutical composition, a person of ordinary skill in the art would be able to determine the appropriate effective dosage of the histidine or its pharmaceutically acceptable salt and proline or its pharmaceutically acceptable salt according to a specific use for improving exercise performance, improving muscle function, and / or preventing, improving, or treating muscle diseases, in light of these factors. The pharmaceutical composition according to the present invention is not particularly limited in its formulation, route of administration, and method of administration as long as it exhibits the effects of the present invention.

[0135] In the present invention, the term "food-grade acceptable" refers to something that is physiologically acceptable and does not typically cause an allergic reaction or a similar reaction when consumed by humans, and the salt is preferably an acid adduct formed by a food-grade acceptable free acid.

[0136] In the present invention, preferred examples of "food-grade acceptable salts" may include the types of "pharmaceutical-grade acceptable salts" described above.

[0137] In the present invention, the term "health functional food" includes both the meanings of "functional food" and "health food."

[0138] In this invention, the term "functional food" is synonymous with "food for special health use (FosHu)," and refers to a food with high medical or health effects that is processed to efficiently exhibit bio-regulatory functions in addition to providing nutrition.

[0139] In the present invention, the term "health food" refers to a food that has an active effect of maintaining or promoting health compared to general food, and "health supplement food" refers to a food intended for the purpose of supplementing health. Depending on the case, the terms functional food, health food, and health supplement food are used interchangeably. The above-mentioned food may be manufactured in various forms such as tablets, capsules, powders, granules, liquids, and pills.

[0140] As a specific example of such a functional food, a processed food can be manufactured using the above composition to modify agricultural, livestock, or fishery products while preserving their characteristics and improving their shelf life.

[0141] The health functional food composition of the present invention may also be manufactured in the form of nutritional supplements and food additives, and is intended for human consumption.

[0142] The above-mentioned type of food composition can be prepared in various forms according to conventional methods known in the art. General foods may be prepared by adding histidine or a food-grade salt thereof and proline or a food-grade salt thereof to beverages (including alcoholic beverages), fruits and their processed foods (e.g., canned fruit, jarred fruit, jam, marmalade, etc.), fish, meat and their processed foods (e.g., ham, sausage, corned beef, etc.), breads and noodles (e.g., udon, buckwheat noodles, ramen, spaghetti, macaroni, etc.), fruit juices, various drinks, cookies, malt syrup, dairy products (e.g., butter, cheese, etc.), edible vegetable oils, margarine, vegetable proteins, retort foods, frozen foods, various seasonings (e.g., soybean paste, soy sauce, sauces, etc.).

[0143] In addition, nutritional supplements may be manufactured by adding histidine or a food-grade salt thereof and proline or a food-grade salt thereof to capsules, tablets, pills, etc., although not limited thereto.

[0144] In addition, as a health functional food, the above-mentioned histidine or its food-grade acceptable salt and proline or its food-grade acceptable salt may be consumed by liquefying, granulating, encapsulating, and powdering so that they can be prepared in the form of tea, juice, and drink (health beverage). In addition, the above-mentioned histidine or its food-grade acceptable salt and proline or its food-grade acceptable salt may be prepared in the form of a powder or concentrate to be used as a food additive. Furthermore, the above-mentioned histidine or its food-grade acceptable salt and proline or its food-grade acceptable salt may be prepared in the form of a composition by mixing them with a known active ingredient known to be effective in improving exercise performance, improving muscle function, and / or preventing, improving, or treating muscle diseases.

[0145] When the food composition of the present invention is used as a health drink composition, the health drink composition may contain various flavoring agents or natural carbohydrates as additional ingredients, as in conventional beverages. The aforementioned natural carbohydrates may be monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; or sugar alcohols such as xylitol, sorbitol, and erythritol. Sweeteners may include natural sweeteners such as thaumatin and stevia extract; or synthetic sweeteners such as saccharin and aspartame. The proportion of the natural carbohydrates is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.

[0146] Histidine or a food-grade salt thereof and proline or a food-grade salt thereof may be included as active ingredients in a food composition for improving exercise performance, improving muscle function and / or preventing or improving muscle diseases, and the amount thereof is an amount effective for obtaining the above effects, for example, preferably 0.01 to 100 weight% with respect to the total weight of the composition, but is not particularly limited thereto.

[0147] In addition to the above, the health functional food of the present invention may contain various nutritional supplements, vitamins, electrolytes, flavoring agents, coloring agents, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, or carbonating agents. Furthermore, the health food of the present invention may contain fruit pulp for the production of natural fruit juice, fruit juice beverages, or vegetable beverages. These ingredients may be used independently or in combination. Although the proportion of these additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

[0148] In the present invention, the term "feed" refers to a substance that supplies organic or inorganic nutrients necessary to sustain the life of an animal. The feed includes nutrients such as energy, protein, lipids, vitamins, and minerals required by animals such as livestock, and may be plant-based feed such as grains, root vegetables, food processing by-products, algae, fibers, oils, starches, meal, and grain by-products, or animal-based feed such as proteins, inorganic substances, oils, minerals, oils, and single-cell proteins, but is not limited thereto.

[0149] In the present invention, "feed additive" refers to a substance added to feed to improve animal productivity or health, and is not particularly limited thereto, but may additionally include amino acid preparations, vitamin preparations, enzyme preparations, flavoring agents, silicate preparations, buffering agents, extractants, oligosaccharides, etc. for growth promotion, disease prevention, etc.

[0150] The content of histidine or its salt and proline or its salt included in the feed additive of the present invention is not particularly limited thereto, but may be, for example, 0.001 to 1% (w / w), 0.005 to 0.9% (w / w), or 0.01 to 0.5% (w / w).

[0151] Preferred examples of "salt of histidine (salt thereof)" and "salt of proline (salt thereof)" included in the feed additive of the present invention may include the types of the aforementioned "pharmaceutically acceptable salt" and "food-acceptable salt."

[0152] In the present invention, the term "individual" refers to a normal individual requiring improvement in motor performance, improvement in muscle function, or strengthening of muscle power, as well as an individual that has already developed or may develop a muscle disease. The term "individual" refers to all mammals, including dogs, cattle, horses, rabbits, mice, rats, chickens, or humans; however, the mammals of the present invention are not limited by the above examples. The term "individual" may be an individual excluding humans, but is not limited thereto. The term does not indicate a specific age or gender. Therefore, it is intended to include females / females or males / males, adults / adults and newborns, as well as fetuses. "Patient" refers to an individual afflicted with a disease or disability. The term "patient" includes human and veterinary subjects.

[0153] According to one embodiment, the individual may be a human being aged approximately 50 years or older, approximately 55 years or older, approximately 60 years or older, or approximately 65 years or older. According to another embodiment, the individual may exclude humans aged approximately 50 years or older, approximately 55 years or older, approximately 60 years or older, or approximately 65 years or older.

[0154] According to another embodiment, the individual may be a human patient with type 2 diabetes who has excessive loss of skeletal muscle. According to yet another embodiment, the individual may be a human patient who has excessive loss of skeletal muscle but does not suffer from diabetes. In yet another embodiment, the individual may be excluded from being a diabetic patient.

[0155] According to another embodiment, the individual may be a human patient who has developed muscle dysfunction, muscle atrophy, muscle wasting, or muscle degeneration due to a gene mutation.

[0156] According to another embodiment, the individual may be a patient who has received, is receiving, or will receive anticancer treatment, particularly chemotherapy.

[0157] According to another embodiment, the subject is a subject requiring improved athletic performance, and may be in a state of lacking or insufficient athletic performance in relation to specific training requirements. The subject requiring improved athletic performance may be experiencing symptoms of fatigue and / or muscle fatigue. The subject requiring improved athletic performance may be a subject who intends to perform physical exertion, particularly in an athletic competition or contest.

[0158] According to another embodiment, the subject may be a subject who wishes to improve or enhance their athletic performance. The subject who wishes to improve their athletic performance may not have insufficient or inadequate athletic performance, but may be a subject who wishes to increase or strengthen their athletic performance compared to their normal state. The subject who requires improved athletic performance may be a subject who wishes to perform physical exertion, particularly in an athletic competition or contest.

[0159] A person skilled in the art will know that the optimal dosage and dosing interval of individual doses of histidine or its salts and proline or its salts will be determined by the nature and severity of the disease being treated, the formulation, route and site of administration, and the age and health status of the specific patient being treated, and that a physician will ultimately determine the appropriate dosage to be used. Such administration may be repeated as frequently as appropriate. If adverse effects occur, the dosage and frequency may be changed or reduced in accordance with ordinary clinical practice.

[0160] The administration route of histidine or its salt and proline or its salt may be any general route as long as it can reach the target tissue. The histidine or its salt and proline or its salt according to the present invention may be administered intraperitoneally, intravenously, subcutaneously, intradermally, or orally as intended, but are not limited thereto. Additionally, said histidine or its salt and proline or its salt may be administered by any device capable of moving to target cells.

[0161] The present invention will be explained in more detail below through examples. However, as the present invention is susceptible to various modifications and may take various forms, the specific examples and descriptions provided below are intended only to aid in understanding the invention and are not intended to limit the invention to the specific disclosed forms. The scope of the present invention should be understood to include all modifications, equivalents, and substitutions that fall within the spirit and technical scope of the invention.

[0162] [Example 1]

[0163] Evaluation of muscle function improvement following histidine and proline (HISPRO, HP) treatment

[0164] 1-1. Rearing of Experimental Animals and Administration of Drugs

[0165] Seven-week-old male ICR mice were purchased from Coatec, and Purina mouse food was purchased for the animals. L-histidine and L-proline were purchased from Sigma-Aldrich.

[0166] Upon arrival, mice were housed in a constant temperature and humidity chamber maintaining a temperature of 23±3℃, humidity of 50%, and a 12-hour light-dark cycle, with free access to feed and water. After acclimatizing to the environment for one week, the mice's body weights were measured, and they were randomly distributed into eight groups as shown in Table 1 to ensure uniform average body weights, after which the drugs were administered. All drugs except whey were administered orally once daily for three months, while whey was administered as drinking water once daily for three months. The control group (CTRL) was orally administered the same amount (200μl) of distilled water.

[0167] Group Setup and Drug Administration Group Size Drug Administration Control Group (CTRL) 6 Distilled water 200 μl Experimental Group 1 (HP 17.5) 6 Histidine 17.5 mg / kg and Proline 17.5 mg / kg Experimental Group 2 (HP 175) 6 Histidine 175 mg / kg and Proline 175 mg / kg Experimental Group 3 (Zn 10) 6 Zinc gluconate (based on elemental zinc) 10 mg / kg Experimental Group 4 (Zn10 HP2.5) 6 Zinc gluconate (based on elemental zinc) 10 mg / kg, Histidine 2.5 mg / kg and Proline 2.5 mg / kg Experimental Group 5 (Zn2.5 HP175) 6 Zinc gluconate (based on elemental zinc) 2.5 mg / kg, Histidine 175 mg / kg and Proline 175 mg / kg Experimental Group 6 (Whey) 6 Whey 6.25 g / kg Experimental Group 7 (Schisandra) 6 Schisandra extract 500 mg / kg

[0168] 1-2. Grip strength test

[0169] To measure changes in muscle strength caused by L-histidine and L-proline, grip strength tests were performed on animals in the normal diet group and the drug administration group. The mice were held by their tails, and the maximum grip strength of the fore and hind paws was measured using a grip strength measuring device (Bioseb) when the tails were pulled backward. Grip strength was measured three times, and the average value was adjusted for body weight. As shown in Figure 1, the experimental results confirmed that the maximum muscle strength of the histidine and proline administration groups increased significantly compared to the normal diet group and other experimental groups.

[0170] [Example 2]

[0171] Measurement of changes in muscle gene expression following histidine and proline (HISPRO) treatment

[0172] After completing a 3-month administration period, the animals were euthanized to isolate the gastrocnemius and soleus muscles. RNA was extracted from the muscle tissues using NucleoZOL (MACHEREY-NAGEL) according to the manufacturer's total RNA isolation protocol, and cDNA was synthesized by inducing a Reverse Transcription Polymerase Chain Reaction (RT-PCR) with 1 µg of RNA using ReverTra Ace qPCR RT Master Mix (Toyobo). Real-time PCR was performed on the synthesized cDNA using primer sets for Myh-1, AK-4, AGK, Mfn-1, and Tfb2m genes, which are known to be involved in muscle function. The expression levels of each gene were quantified and analyzed using SYBR Green Realtime PCR Master Mix (Toyobo). The primers used for real-time PCR were synthesized by Bioneer, and their sequence information is shown in Table 2. Each gene expression value was corrected by dividing it by the expression values ​​of the housekeeping genes Gapdh, β-actin, and Hprt.

[0173] Forward (5'-3') Sequence Number Reverse (5'-3') Sequence Number Mfn-1CGGGGTGACCTTCGAGC1TGCTTCAACAAAATGTGAGCCC2Tfb2m(1)TCAAAGGCCTCACGATCACC3TCAAACGCTTGCGAATCTGC4Myh-1GCATCCCTAAAGGCAGGCTC5CAAACACCGATGACTTGGCG6AK-4CTTTCCACCGAGGTGTGTGT7CTTCTCGGTGACTGTCGCTT8AGKTGCAAAGGCAAAGCCAGAAC9ACATCCATGCCAGACAGGTG10HprtAAATGTCAGTTGCTGCGTCC11TCTACCAGAGGGTAGGCTGG12GapdhCAGTATGACTCCACCCACGG13ATGGGCTTCCCGTTGATGAC14β-actinGGGAAGGTGACAGCATTG15ATGAAGTATTAAGGCGGAAGATT16

[0174] As shown in Figure 2, experimental results confirmed that the expression of the Myh-1 gene, which is involved in muscle contraction, increased in the gastrocnemius muscle of the HP175 administration group compared to the control group. This can be interpreted as supporting the results of increased muscle strength observed in the HP175 administration group.

[0175] In addition, as shown in Figures 3 and 4, it was confirmed that the expression of AK-4, AGK, Mfn-1, and Tfb2m genes, which are related to energy metabolism in mitochondria, did not change with low-concentration administration of HP17.5 in the gastrocnemius and soleus muscles, but increased significantly with high-concentration administration of HP175. On the other hand, in the HP175+Z2.5 administration group, no trend of increased expression of the corresponding genes was observed, confirming that zinc addition actually reduced the efficacy of HP175.

[0176] From the above results, it was found that the supply of L-histidine and L-proline enhances muscle function by strengthening muscle fiber gene expression and enhancing mitochondrial energy metabolism activity gene expression.

[0177] Statistical analysis

[0178] Statistical significance was analyzed using the t-test against the control group. *p<0.05, **p<0.01.

[0179] [Example 3]

[0180] Confirmation of the effects of histidine and proline (HISPRO) on improving skeletal muscle quality and promoting oxidative muscle phenotype

[0181] 3-1. Animals

[0182] Seven-week-old male ICR mice were purchased from KOATECH (Korea). The mice were housed in individual cages at 23±3℃ with a 12-hour light-dark cycle and were allowed to freely consume distilled water and regular feed. Animal experiments were initiated after a one-week acclimatization period. A total of 24 mice were randomly assigned to four groups (n=6 per group) based on average body weight.

[0183] 3-2. Administration of Histidine and Proline (HISPRO)

[0184] L-histidine hydrochloride monohydrate (H5659, Sigma-Aldrich) and L-proline (P5607, Sigma-Aldrich) were dissolved in distilled water. For monotherapy, each amino acid was administered at a dose of 350 mg / kg (Fig. 5a). This dose was selected as the minimum effective concentration based on a prior pilot study. For combined HISPRO treatment, mice were administered 350 mg / kg of each of the two amino acids (total 700 mg / kg). 200 μL was administered orally to mice once daily until the end of the study. The control group received the same dose of distilled water.

[0185] 3-3. Grip Strength Test

[0186] Four-leg grip strength was measured using a dynamometer (BIO-GS4, Bioseb, France). After having the mouse grasp a metal grid with all four legs, it was gently pulled backward until it released the grid. The maximum force was recorded at each attempt, and the average strength (g) of three attempts was calculated.

[0187] 3-4. Rotarod Test

[0188] Motor coordination and balance were measured using an acceleration rotarod (Panlab, Harvard Apparatus, Spain). Mice were placed on the rotating rod, and the latency to fall was recorded. After a short training session, each mouse underwent three trials under conditions of acceleration from 4 to 40 rpm for 300 seconds. The latency to fall was recorded in each trial, and the average value was calculated.

[0189] 3-5. Treadmill

[0190] Endurance was evaluated by measuring the distance traveled using a treadmill device (BLI-TR01M, BeonLi Scientific Instruments, Korea). The electric shock grid delivered a current of 0.1 mA, which was uncomfortable but did not cause physical harm to the animals. Mice were acclimatized to the treadmill the day before the experiment. During the acclimatization session, mice ran for 10 minutes at a speed of 15 m / min on a 5° incline. The following day, mice underwent an endurance test according to the following protocol: 20 minutes at 15 m / min on a 5° incline, 20 minutes at 17 m / min on a 5° incline, 20 minutes at 19 m / min on a 5° incline, 15 minutes at 21 m / min on a 5° incline, 15 minutes at 22 m / min on a 10° incline, followed by running at 24 m / min on a 10° incline until exhaustion. Exhaustion was defined as the inability to resume driving for 10 seconds despite continuous impact, and the total driving distance was calculated.

[0191] 3-6. Histology

[0192] For hematoxylin and eosin (H&E) staining, gastrocnemius muscle was fixed in neutral buffered 10% formalin (HT-501128, Sigma-Aldrich) and embedded in paraffin. Thin sections were deparaffinized and rehydrated, then stained using the H&E method. Stained sections were photographed using a microscope (BX53 upright microscope, Olympus, Japan). A total of 100–140 muscle fibers were analyzed from three images per mouse, and the cross-sectional area (CSA) of individual muscle fibers was measured using ImageJ software according to prior art. For succinate dehydrogenase (SDH) staining, gastrocnemius muscle sections dissected according to prior art were directly embedded in OCT compound (#4583, Tissue-Tek) and rapidly frozen in isopentane cooled with liquid nitrogen. Frozen sections (thickness 10 μm) were stained in a preheated SDH staining solution (1 mg / ml nitroblue tetrazolium (NBT, N6876, Sigma-Aldrich) and 27 mg / ml sodium succinate (S2378, Sigma-Aldrich) in 25 mM phosphate buffer (S9638, Sigma-Aldrich)) at 37°C for 30 minutes. The slides were washed three times with distilled water and mounted. The stained sections were photographed under the same microscope, and SDH-positive fibers were quantified using ImageJ software.

[0193] 3-7. Measurement of In vivo Oxygen Consumption Rate (VO2)

[0194] Whole-body oxygen consumption (VO2) was evaluated using indirect calorimetry with the TSE LabMaster system (TSE Systems, Bad Homburg, Germany), with slight modifications to the previously described method. Mice were individually housed in metabolic cages with free access to food and water under a 12-hour light-dark cycle and conditions of 22±2°C. Following a 24-hour acclimatization period in the calorimetry cage, VO2 was recorded continuously for an additional 24 hours. In this study, lighting was turned on at 06:30 and turned off at 18:30, and VO2 data were averaged by separating them into light (daytime, 06:30–18:30) and dark (nighttime, 18:30–06:30). Oxygen consumption was expressed in ml O2 / kg / hr.

[0195] 3-8. Results

[0196] In the grip strength test, histidine and HISPRO were shown to significantly improve grip strength compared to the control group (Fig. 5b). In the subsequent rotarod and treadmill tests, only HISPRO significantly improved exercise performance and endurance (Figs. 5c and 5d).

[0197] Histological analysis showed that HISPRO significantly increased the cross-sectional area (CSA) of muscle fibers and shifted the fiber size distribution toward larger fibers (Figs. 5e to 5f). SDH staining revealed a higher proportion of oxidative (SDH-positive) muscle fibers in the HISPRO-treated group (Fig. 5h), suggesting a transition to an oxidative muscle phenotype.

[0198] Consistent with this, in vivo oxygen consumption was significantly improved by HISPRO (Figs. 5i and 5j). These results indicate that HISPRO improves muscle function and promotes an oxidative muscle phenotype, reflecting an overall improvement in muscle quality. Although muscle mass did not change significantly in any treatment, improvements in performance, larger CSA fibers, an increased proportion of SDH-positive fibers, and increased VO2 suggest that HISPRO primarily improves muscle quality. Histidine monotherapy slightly improved grip strength without significant effects on rotarod or treadmill performance, while proline monotherapy showed only minimal effects, indicating that combined HISPRO treatment is necessary for complete improvement in motor coordination and endurance.

[0199] [Example 4]

[0200] Confirmation of the effects of histidine and proline (HISPRO) on improving skeletal muscle mitochondrial function and oxidative metabolism

[0201] To elucidate the molecular basis of the functional improvement identified in Example 3, mitochondrial and metabolism-related gene expression, mitochondrial content, enzyme activity, and protein levels were analyzed in the gastrocnemius tissue of HISPRO-treated and control mice.

[0202] 4-1. RNA Analysis

[0203] Total RNA was extracted from muscle tissue using NucleoZOL reagent (740404.200, Macherey-Nagel). 1 μg of total RNA was used for cDNA synthesis using ReverTra Ace qPCR RT Master Mix (Toyobo, Japan). Real-time qPCR (RT-qPCR) was performed using SYBR Green Realtime PCR Master Mix (Toyobo, Japan) and the primer set listed in Table 3.

[0204]

[0205] 4-2. Western Blot

[0206] To confirm changes in oxidative phosphorylation (OXPHOS) complex protein levels induced by HISPRO treatment, OXPHOS complex protein expression was analyzed. Samples were lysed in RIPA buffer supplemented with Halt’s protease and kinase inhibitor cocktail (78446, Thermo). Protein lysates were separated on a Bolt 4-12% Bis-Tris Plus gel (Thermo Scientific) and transferred to a nitrocellulose membrane. After blocking with 5% skim milk powder for 1 hour, the membrane was incubated overnight with the primary antibody at 4°C. Antibodies used: OXPHOS (ab110413, Abcam), Vinculin (#13901, CST), PGC-1α (NBP1-04676, Novus Biologicals), p-AMPK (#2535, CST), AMPK (#5831, CST), GAPDH (#2118, CST), Atrogin-1 (sc-166806, SCBT). Signals were detected using anti-rabbit or anti-mouse HRP-conjugated secondary antibodies.

[0207] 4-3. Measurement of mtDNA Copy Number

[0208] Mitochondrial DNA content was measured using the previously described D-loop quantification method. Total genomic DNA was extracted from the gastrocnemius muscle using the Solg® Genomic DNA Prep Kit (Solgent, Korea) according to the manufacturer's instructions. To determine the copy number of mitochondrial DNA (mtDNA), quantitative real-time PCR (qPCR) was performed using the extracted total DNA as a template. The D-loop region of the mitochondrial genome was selected as the amplification target to represent the mtDNA level. The qPCR reaction was performed using THUNDERBIRD® Next SYBR® qPCR Mix (Toyobo, Japan). For data normalization, the 18s rRNA gene encoded by nuclear DNA (nDNA) was used as an internal control. The specific primer sequences used are listed in Table 3.

[0209] 4-4. Citric Acid Synthetase Activity

[0210] To evaluate mitochondrial function, citric acid synthase activity in protein lysates from gastrocnemius muscle tissue was measured according to the manufacturer's protocol using a commercial assay kit (CS0720, Sigma-Aldrich). Briefly, protein lysates from gastrocnemius muscle tissue were incubated for 1.5 minutes with 0.3 mM acetyl-CoA and 0.1 mM 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) in assay buffer at 37°C. After measuring the baseline value at 412 nm, the reaction was initiated by adding oxaloacetate to a final concentration of 0.5 mM. Subsequently, the increase in absorbance was measured kinetically for 1.5 minutes at 37°C. Citric acid synthase activity was calculated according to the manufacturer's instructions.

[0211] 4-5. Results

[0212] HISPRO treatment significantly upregulated genes associated with mitochondrial biogenesis (Pgc-1α, ERRα, Tfam, Tfb1m, Gabpb1), mitochondrial dynamics (Mfn2, Drp1), and metabolic regulation (FoxO1, Sirt1) (Figs. 6a and 7). Consistent with this, genes involved in fatty acid oxidation and oxidative metabolism, including PPARα, mCAD, Acox1, and FH, also significantly increased (Fig. 6b). Along with these transcriptional changes, mtDNA copy number and citric acid synthase activity significantly increased in the HISPRO-treated group (Figs. 6c and 6d), indicating improvements in mitochondrial content and function. Furthermore, protein levels of the oxidative phosphorylation (OXPHOS) complex increased, with significant increases observed in complexes I, III, IV, and V (Figs. 6e and 6f). In addition, in gastrocnemius muscle treated with HISPRO, several genes associated with type I (slow-twitch) muscle fibers were upregulated, and genes associated with type II (fast-twitch) muscle fibers were downregulated (Fig. 6g). These results suggest that HISPRO promotes mitochondrial biosynthesis and induces a transition to a more oxidative muscle phenotype.

[0213] [Example 5]

[0214] Confirmation of the Enhancing Effects of Histidine and Proline (HISPRO) on SIRT1 Activity and AMPK Phosphorylation in Skeletal Muscle

[0215] 5-1. RNA Analysis

[0216] Based on the transcriptional changes observed in Example 4, it was hypothesized that HISPRO activates the SIRT1 signaling axis, a key regulator of cellular energy metabolism. To confirm this, the expression of NAMPT and NMNAT, which are genes related to NAD synthesis, was analyzed using the primer set in Table 3 under the same conditions as the RNA analysis in Example 4-1.

[0217] 5-2. Measurement of NAD / NADH Ratio

[0218] To further confirm SIRT1 activity, the NAD / NADH ratio was measured in gastrocnemius tissue.

[0219] 5-3. Western Blot

[0220] To confirm the change in protein levels caused by HISPRO treatment, the protein levels of PGC-1α, p-AMPK, and AMPK were analyzed under the same conditions as the Western blot of Example 4-2.

[0221] 5-4. Immunoprecipitation

[0222] To indirectly confirm the deacetylase activity of SIRT1, the acetylation levels of FOXO1 and LKB1 in gastrocnemius muscle tissue were analyzed by immunoprecipitation. 200 μg of protein lysate was immunoprecipitated overnight at 4°C using 1 μg of antibody (α-FOXO1 or α-LKB1) and 20 μl of protein G agarose beads (PROTGA-RO, Sigma-Aldrich). After washing the immunocomplex beads three times, they were heated in sample buffer, and immunoblotting was performed using anti-acetylated lysine (#9814, #9681, CST), anti-FOXO1 (#2880, CST), and anti-LKB1 (sc-32245, SCBT) antibodies.

[0223] 5-5. Results

[0224] HISPRO treatment significantly increased NAD synthesis-related genes, including NAMPT and NMNAT, and raised the NAD / NADH ratio (Figs. 8a to 8c), indicating an enhancement in SIRT1 activity. HISPRO also increased PGC-1α protein levels and decreased the acetylation of FOXO1 and LKB1 (Figs. 8d and 8e). Furthermore, given that LKB1 is an upstream kinase of AMPK, HISPRO treatment significantly increased AMPK phosphorylation (Fig. 8f), indicating activation of the SIRT1-PGC-1α-AMPK signaling axis in skeletal muscle.

[0225] [Example 6]

[0226] Confirmation of the effects of histidine and proline (HISPRO) on mitochondrial biosynthesis and OXPHOS expression under SIRT1 inhibition conditions

[0227] To determine whether the metabolic effect of HISPRO depends on SIRT1 activity, the effect of HISPRO was evaluated in C2C12 myotubes with inhibited SIRT1 using the SIRT1 inhibitor EX-527.

[0228] 6-1. Cell Culture and Processing

[0229] C2C12 myoblasts were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-antifungal agent (15240062, Gibco). To induce differentiation into myotubes, the growth medium was replaced with differentiation medium containing DMEM supplemented with 2% horse serum. The differentiation medium was replaced every 2 days for a total of 3 times (over 6 days). After differentiation, cells were cultured in serum-free medium and treated with 5 mM HISPRO (2.5 mM L-histidine (H6034, Sigma-Aldrich) + 2.5 mM L-proline (P5607, Sigma-Aldrich)) and 10 μM EX-527 (E7034, Sigma-Aldrich) for 24 hours.

[0230] 6-2. RNA Analysis

[0231] Mitochondrial biosynthesis-related gene expression was analyzed using the primer set in Table 3 below under the same conditions as the RNA analysis in Example 4-1.

[0232] 6-3. Measurement of Mitochondrial Density

[0233] To confirm the effect of HISPRO on mitochondrial density and its dependence on SIRT1, C2C12 myotube cells cultured in confocal culture dishes were treated for 24 hours, then incubated in serum-free medium with 50 nM MitoTracker (M22426, Invitrogen) and 2 μg / ml Hoechst 33342 (B2261, Sigma-Aldrich) in a CO2 incubator at 37°C for 30 minutes. Cells were washed twice with HBSS, fixed with 4% PFA for 30 minutes at room temperature, and then confocal imaging was performed (Fluoview FV3000 confocal microscope, Olympus). MitoTracker fluorescence was detected at Ex644 / Em665 nm, and Hoechst 33342 at Ex350 / Em461 nm. Mitochondrial density was calculated using ImageJ software as the ratio of the deep red fluorescence area to the myotube cell area within each field of view.

[0234] 6-4. Western Blot

[0235] To confirm the effect of HISPRO on OXPHOS complex protein expression under SIRT1 inhibition conditions, OXPHOS complex protein levels were analyzed under the same conditions as the Western blot of Example 4-2 (n=5 per group).

[0236] 6-5. Results

[0237] Treatment with 5 mM HISPRO significantly increased the expression of mitochondrial biosynthesis-related genes, including Tfam, Tfb1m, and Tfb2m, compared to the control group. However, this effect was significantly reduced by co-treatment with EX-527 (Fig. 8g). Consistent with this, the increase in mitochondrial density induced by HISPRO was also reduced in the presence of EX-527 (Fig. 8h), indicating that the mitochondrial biosynthetic effect of HISPRO is highly dependent on SIRT1 activity. On the other hand, even under SIRT1 inhibition, OXPHOS complex proteins showed a non-significant tendency toward higher levels in HISPRO-treated cells, but this did not reach statistical significance (Fig. 9). This suggests that the effect of HISPRO on OXPHOS may involve additional SIRT1-independent mechanisms.

[0238] [Example 7]

[0239] Confirmation of Muscle-Protective and Mitochondrial Function Restoration Effects of Histidine and Proline (HISPRO) in a Dexamethasone-Induced Muscle Atrophy Model

[0240] 7-1. Dexamethasone-induced muscle atrophy model

[0241] Seven-week-old male C57BL / 6 mice were purchased from KOATECH (Korea). After a one-week acclimatization period, the mice were randomized into three groups (CTRL, n=6; Dexa, n=8; HISPRO, n=8). The Dexa and HISPRO groups were administered dexamethasone (25 mg / kg, intraperitoneal injection) and either distilled water or HISPRO (700 mg / kg) orally once daily for 14 days, respectively. The control group received normal saline (intraperitoneal injection) and distilled water (oral administration) (Fig. 10a).

[0242] 7-2. Muscle Function Assessment

[0243] To evaluate muscle function, grip strength tests and rotarod tests were performed under the same conditions as in Examples 3-3 and 3-4.

[0244] 7-3. RNA Analysis

[0245] Under the same conditions as the RNA analysis of Example 4-1, the expression of genes related to mitochondrial biosynthesis and function and genes related to muscle atrophy in gastrocnemius muscle tissue was analyzed using the primer set in Table 3 below.

[0246] 7-4. Measurement of Citric Acid Synthase Activity

[0247] To confirm the recovery of mitochondrial function, the citric acid synthase activity of the gastrocnemius muscle tissue was measured under the same conditions as in Example 4-4.

[0248] 7-5. Western Blot

[0249] To confirm changes in muscle atrophy-related protein expression, Atrogin-1 protein levels were analyzed under the same conditions as the Western blot of Example 4-2. Vinculin was used as an internal control.

[0250] 7-6. Results

[0251] While dexamethasone treatment significantly impaired muscle function, HISPRO administration significantly improved muscle performance compared to the dexamethasone-treated group (Figs. 10b and 10c). Consistent with observations in normal mice, HISPRO restored the expression of genes related to mitochondrial biosynthesis and function that were suppressed by dexamethasone (Fig. 10d). Additionally, HISPRO treatment increased citric acid synthase activity (Fig. 10e), indicating an improvement in mitochondrial function. Notably, HISPRO treatment significantly downregulated the expression of genes related to muscle atrophy, including Atrogin-1 and MuRF1 (Fig. 10f), and Atrogin-1 protein levels were consistently reduced (Fig. 10g). Collectively, these results demonstrate that HISPRO alleviates dexamethasone-induced muscle wasting, at least in part, through the restoration of mitochondrial function.

[0252] Statistical analysis

[0253] Statistical analysis was performed using GraphPad Prism v.6.0. Data were displayed as box-whisker plots (median, IQR, min-max whiskers). Grubbs tests were applied beforehand, and up to one outlier per group was excluded when p < 0.05. Differences between the two groups were evaluated using non-paired t-tests, while multiple group comparisons were evaluated using one-way ANOVA with Sidak post-hoc tests. A p-value less than 0.05 was considered statistically significant.

Claims

1. Histidine or a pharmaceutically acceptable salt thereof; and A pharmaceutical composition for improving exercise performance comprising proline or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition according to claim 1, exhibiting one or more of the following effects i) to viii): i) Inhibition of muscle loss; ii) Increase in grip strength; iii) Increase in motor coordination; iv) Improvement of endurance; v) Increased tolerance to muscle fatigue; vi) Increased sense of balance; vii) Increase in muscle energy production; and viii) Inhibition of muscle atrophy.

3. Histidine or a food-grade acceptable salt thereof; and A health functional food composition for improving exercise performance comprising proline or a food-grade acceptable salt thereof.

4. A health functional food composition according to paragraph 3, exhibiting one or more of the following effects i) to viii): i) Inhibition of muscle loss; ii) Increase in grip strength; iii) Increase in motor coordination; iv) Improvement of endurance; v) Increased tolerance to muscle fatigue; vi) Increased sense of balance; vii) Increase in muscle energy production; and viii) Inhibition of muscle atrophy.

5. Histidine or its salt; and A feed additive for improving exercise performance comprising proline or a salt thereof.

6. Histidine or a pharmaceutically acceptable salt thereof; and A pharmaceutical composition for improving muscle function or preventing or treating muscle diseases, comprising proline or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition according to claim 6, wherein the muscle disease is a muscle disease resulting from decreased muscle function, muscle atrophy, muscle wasting, or muscle degeneration.

8. A pharmaceutical composition according to claim 6, wherein the muscle disease is one or more selected from the group consisting of atony, muscular atrophy, muscular dystrophy, myasthenia gravis, cachexia, sarcopenia, cardiomyopathy, and cardiac atrophy.

9. A pharmaceutical composition according to claim 6, exhibiting one or more of the following effects i) to viii): i) Inhibition of muscle loss; ii) Increase in grip strength; iii) Increase in motor coordination; iv) Improvement of endurance; v) Increased tolerance to muscle fatigue; vi) Increased sense of balance; vii) Increase in muscle energy production; and viii) Inhibition of muscle atrophy.

10. Histidine or a food-grade acceptable salt thereof; and A health functional food composition for improving muscle function or preventing or improving muscle diseases, comprising proline or a food-grade acceptable salt thereof.

11. A health functional food composition according to claim 10, wherein the muscle disease is a muscle disease caused by decreased muscle function, muscle atrophy, muscle wasting, or muscle degeneration.

12. A health functional food composition according to claim 10, wherein the muscle disease is one or more selected from the group consisting of atony, muscular atrophy, muscular dystrophy, myasthenia gravis, cachexia, sarcopenia, cardiomyopathy, and cardiac atrophy.

13. A health functional food composition according to claim 10, exhibiting one or more of the following effects i) to viii): i) Inhibition of muscle loss; ii) Increase in grip strength; iii) Increase in motor coordination; iv) Improvement of endurance; v) Increased tolerance to muscle fatigue; vi) Increased sense of balance; vii) Increase in muscle energy production; and viii) Inhibition of muscle atrophy.

14. Histidine or its salt; and A feed additive for improving muscle function or preventing or improving muscle diseases, comprising proline or a salt thereof.

15. Histidine or its salt; and A composition for strengthening muscles comprising proline or a salt thereof.

16. A method for improving exercise performance comprising administering an effective amount of a composition comprising histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients to an individual in need thereof.

17. A method for improving muscle function or preventing, improving, or treating muscle disease, comprising administering an effective amount of a composition containing histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients to an individual in need thereof.

18. A method for strengthening muscle strength comprising administering an effective amount of a composition comprising histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients to an individual in need thereof.

19. Use of a composition comprising histidine or a pharmaceutically or food-grade acceptable salt thereof and proline or a pharmaceutically or food-grade acceptable salt thereof as active ingredients for the manufacture of a pharmaceutical or health functional food for improving exercise performance.

20. Use of a composition comprising histidine or a pharmaceutically or food-grade salt thereof and proline or a pharmaceutically or food-grade salt thereof as active ingredients for the manufacture of a pharmaceutical or health functional food for improving muscle function or preventing, improving, or treating muscle diseases.

21. Use of a composition comprising histidine or a pharmaceutically or food-grade salt thereof and proline or a pharmaceutically or food-grade salt thereof as active ingredients for the manufacture of a muscle-strengthening drug or health functional food.